Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis

Table 1 Correlation between CLDN7 immunostaining intensity and clinicopathological features in 129 ccRCC patients from Peking University First Hospital (*, p < 0.05. **, p < 0.01)

Clinicopathological features		CLDN7 immunostaining intensity				p value
Clinicopathological features		0	1	2	3	p value
Gender	Female	38	39	8	2	0.318
Gender	Male	21	13	5	3
Age(median 55, year)	<=55	34	29	3	0	0.013*
Age(median 55, year)	> 55	25	23	10	5
Laterality	Left	24	27	4	4	0.176
Laterality	Right	35	25	9	1
Pathologic T	T1	47	44	9	1	0.001**
	T2	2	5	1	0
	T3	10	3	3	4
Histologic grade	G1	10	6	1	0	0.044*
	G2	39	40	7	2
	G3	7	5	5	3
	G4	3	1	0	0
DFS	Disease free	40	52	12	4	< 0.001**
DFS	Recurrence, metastasis or death	19	0	1	1
Creatinine	Normal	47	46	10	3	0.484
Creatinine	Elevated	11	5	1	1
Urea nitrogen	Normal	48	45	11	3	0.803
Urea nitrogen	Elevated	9	6	1	1

DFS Disease Free Survival. Follow up (1–56 month). Recurrence 9, Metastasis 11 and Death 1

ISSN: 1756-9966